close

Mergers and Acquisitions

1 2 3 28
Number of results: 552
Date Acquired company Acquiring company Amount Related
2017-03-23 Agalimmune (UK) Bioline Rx (Israel) $6 million and additional future payments based on development and commercial milestones Cancer - Oncology
2017-03-23 Euchloe Bio (Singapore) Tessa Therapeutics (Singapore) undisclosed Cancer - Oncology
2017-03-17 Threshold Pharmaceuticals (USA - CA) Molecular Templates (USA - TX) Cancer - Oncology
2017-03-16 PCT, a Caladrius Company (USA - CA) Hitachi Chemical Co. America (USA - CA) $75 million in cash and $5 million revenue-based milestone Technology - Services Production - Manufacturing
2017-02-16 Ariad Pharmaceuticals (USA - MA) Takeda Pharmaceutical (Japan) $5.2 billion

Cancer - Oncology

2017-02-13 Zeltiq Aesthetics (USA - CA) Allergan (Ireland) $2.475 billion

Aesthetic medicine

2017-01-26 Actelion (Switzerland) Johnson&Johnson (J&J) (USA - NJ) $ 30 billion

Rare diseases

2017-01-26 Delinia (USA - MA) Celgene (USA - NJ) up to $ 775 million

Autoimmune diseases

2017-01-25 Xpand Biotechnology (The Netherlands) Kuros Biosciences (Switzerland)
2017-01-24 GenVec (USA - MD) Intrexon (USA - MD)

Gene therapy

2017-01-19 Martindale Pharma (UK) Ethypharm (France)
2016-12-29 Villapharma (Spain) Eurofins Scientific (Luxembourg)
2016-12-22 Genticel (France) Genkyotex (Switzerland) € 30 million

Cancer-Oncology

Infectious diseases

2016-12-20 LifeCell Corporation (USA - NJ) Allergan (Ireland) $2.9 Billion

Regenerative medicine

2016-12-16 Ziarco Group (USA) Novartis (Switzerland) undisclosed

Dermatological diseases

2016-12-15 TangenX Technology (USA - MA) Repligen (USA - MA) €37 million ($ 39 million)

Technology - Services

2016-12-10 Encore Vision (USA - TX) Novartis (Switzerland) undisclosed Ophtalmological diseases
2016-12-07 Lonza's peptides business and operations in Brain-l'Alleud PolyPeptide Laboratories (USA - CA) undisclosed

Technology - Services

2016-12-02 Acetylon Pharmaceuticals (USA - MA) Celgene (USA - NJ) undisclosed

Cancer - Oncology

Autoimmune diseases

2016-11-30 G7 Therapeutics (Switzerland) Heptares Therapeutics (UK), a wholly-owned subsidiary of Sosei Group (Japan) CHF 12 million

Technology - Services